Not many biotechs survive beyond 25 years, let alone get multiple drugs approved and turn a profit. BioMarin Pharmaceutical has done all that, but finds itself navigating ...

Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ahead of many investors ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to ...

CK-4015089 is under clinical development by Cytokinetics and currently in Phase I for Muscular Dystrophy. According to GlobalData, Phase I drugs for Muscular Dystrophy does not have sufficient ...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 31, 2024 it granted stock options to purchase an aggregate of ...

Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of ...

Balling runs in the James family blood. In a Jan. 1 post to Instagram, Bryce shared a picture of himself donning an Arizona basketball jersey with a caption confirming that he has fully committed ...

Bryce James, the younger son of basketball legend LeBron James, has committed to the University of Arizona as a member of the Wildcats’ 2025 class. The 17-year-old made the announcement on ...